Skip to main content

Clifford Chance

Clifford Chance


Pharma and Healthcare Sectors are ripening for whistleblowing at a time when EU Regulations may Complicate Investigations

25 October 2021

There are several factors at play for companies in the pharma and healthcare sectors, which, when combined with the availability of rewards for whistleblowers under several US laws, as well as the EU's forthcoming whistleblowing regime, create an environment that is ripe for whistleblowing. Companies in all sectors need to be prepared, with factors in sectors like pharma and healthcare indicating the possibility of a surge in whistleblowing activity.

Download PDF